Pipeline Overview
| Product | Mechanism | Ownership | Indication | Preclinical | Clinical Proof-of-Concept | Pivotal |
|---|---|---|---|---|---|---|
| CG-806 | BTK (wildtype and mutant) | Aptose: WW Crystal Genomics: Korea |
CLL & NHL |
complete
CLL & NHL
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| CG-806 | FLT3 (wildtype and mutant) | Aptose: WW Crystal Genomics: Korea |
AML |
complete
AML
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| APTO-253 | MYC | Aptose: WW | AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
| APL-581 | BRD4/JAK | Aptose and Ohm | Hematologic Cancers |
in progress
Hematologic Cancers
Preclinical Phase in progress
|
not started
Clinical Proof-of-Concept Phase not started
|
not started
Pivotal Phase not started
|
CG-806 for B-cell Tumors
Oral, Mutation-Agnostic FLT3/BTK Inhibitor
CG-806 is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
View Candidate
CG-806 for Myeloid Tumors
Oral, Mutation-Agnostic FLT3/BTK Inhibitor
CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.
View Candidate
APTO-253 for Myeloid Tumors
First-in-class MYC Inhibitor
APTO-253 is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
View Candidate
Posters & Presentations
Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.
View Posters & Presentations